Randomized Controlled Trial of Repeat vs. Single Quadratus Lumborum Block to Reduce Opioid Prescriptions After Open Resection of Retroperitoneal Sarcoma ("RESQU-SARC" Trial)
The RESQU-SARC trial, sponsored by M.D. Anderson Cancer Center, aims to evaluate the efficacy of repeat versus single quadratus lumborum blocks in reducing opioid prescriptions post-surgery for retroperitoneal sarcoma patients. Given the increasing scrutiny on opioid prescriptions due to addiction concerns, this trial addresses a significant market need for effective pain management alternatives. The successful outcome could position liposomal bupivacaine as a preferred option in postoperative pain management, potentially influencing market dynamics and competitive positioning against existing analgesics. The collaboration with the National Cancer Institute (NCI) further enhances credibility and may facilitate broader adoption within clinical settings.
Indication: Retroperitoneal Sarcoma
Modality: small molecule
Target: Liposomal bupivacaine injection (Quadratus Lumborum Block)
Sponsor: M.D. Anderson Cancer Center
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 02, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Liposomal bupivacaine injection (Quadratus Lumborum Block)
View original source fields
Condition raw: Retroperitoneal Sarcoma
Condition normalized: Retroperitoneal Sarcoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Liposomal bupivacaine injection (Quadratus Lumborum Block)
Target normalized: Liposomal bupivacaine injection (Quadratus Lumborum Block)